Literature DB >> 3001571

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

J Benavides, J C Camelin, N Mitrani, F Flamand, A Uzan, J J Legrand, C Gueremy, G Le Fur.   

Abstract

Two models have been chosen to study the effect of 2-amino-6-trifluoromethoxy benzothiazole (PK 26124) on excitatory amino acid neurotransmission: the pool of cyclic guanosine monophosphate (cGMP) in the cerebellum and the release of acetylcholine in the striatum and olfactory tubercles. The release of acetylcholine induced by N-methyl-DL-aspartate in the striatum and olfactory tubercles was antagonized by PK 26124 which was less potent on the release of acetylcholine induced electrically. The increase in levels of cGMP in the cerebellum induced by excitatory amino acids such as glutamate and quisqualate was antagonized by PK 26124, but the drug was inactive against N-methyl-DL-aspartate, L-aspartate, kainate and cysteine sulphinate. In vivo it antagonized the increases of cGMP in the cerebellum elicited by all these excitatory compounds. All these results are compatible with a possible antagonism by PK 26124 of the excitatory amino acid neurotransmission and may explain its anticonvulsant properties.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001571     DOI: 10.1016/0028-3908(85)90196-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  23 in total

1.  Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.

Authors:  M Sommer; F Tergau; S Wischer; C D Reimers; W Beuche; W Paulus
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

2.  Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice.

Authors:  D J Sanger; D Joly
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 4.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

5.  Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats.

Authors:  J M Stutzmann; P Cintrat; P M Laduron; J C Blanchard
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Proceedings of the British Pharmacological Society. Cambridge, 8th-10th April 1987. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

7.  Effects of riluzole on electrically evoked neurotransmitter release.

Authors:  T Jehle; J Bauer; E Blauth; A Hummel; M Darstein; T M Freiman; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 8.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Enhanced excitability of guinea pig inferior mesenteric ganglion neurons during and following recovery from chemical colitis.

Authors:  David R Linden
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.